Nocion Therapeutics is developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain
Nocion Therapeutics is developing novel small molecule CSCBs, “nocions,” that selectively affect actively firing nociceptors for the treatment of serious conditions involving cough, itch, and pain
Think Research develops knowledge-based and leading clinical content tools that empower clinicians to deliver the best evidence-based care to patients and drive greater patient outcomes.
Morphotek was acquired by Eisai in April 2007 for $325 million, with a pipeline of treatments for oncology, inflammatory, and infectious diseases.
Developer of novel therapeutics for kidney disease, KAI Pharmaceuticals was acquired by Amgen in 2012 for US$315 million.
From the time we invested in 2002 to our exit in 2006, ISTA Pharmaceuticals launched 3 products in the United States to treat diseases of the eye.
Guava Technologies was acquired by Millipore Inc. in February 2009, having developed and manufactured unique flow cytometry systems.
Lumira Ventures led a PIPE in Depomed in 2003 and fully exited in 2006 after the FDA approved the company’s two lead products in 2005 for treatment of pain and diseases of the central nervous system.
Corus Pharmaceuticals, developer of Aztreonam for the treatment of cystic fibrosis and Lidocaine for the treatment of oral corticosteroid-dependent asthma, was acquired by Gilead in August 2006 for $365 million.
Ception Therapeutics was acquired by Cephalon Inc. in March 2010 for $350 million plus significant future millstones with its lead product which was subsequently approved to treat eosinophilic asthma.
Pharmasset was acquired by Gilead in 2011 for $11 billion, having developed the first oral therapeutic for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Forbius was acquired by Bristol Myers Squibb in August 2020, a company targeting hard-to-drug TFG-beta and EGFR pathways in Fibrosis and Cancer.
Engage Therapeutics was acquired by UBC for up to US$270 million in June 2020, having developed the first on-demand rescue treatment for the rapid termination of active epileptic seizures.
Transposon Therapeutics specializes in the development of genetic therapeutics for the treatment of neurodegenerative diseases.
COUR Pharmaceuticals is developing first-in-class therapies designed to achieve antigen-specific tolerance for immune-mediated disease.
Endogenex is shifting the treatment paradigm for people living with Type 2 Diabetes by resetting cellular signaling to help the body better manage blood sugar levels.
X4 Pharmaceuticals a leader in the discovery and development of novel therapies for the treatment of immune system diseases.
Thryv Therapeutics is pioneering a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias.
Specific Biologics is developing a next generation gene-editing platform to accurately edit cells in a target tissue to treat certain genetic diseases.
Medexus Pharmaceuticals is developing a best-in-class portfolio of innovative and high-valued orphan treatments for rare disease.
Kalgene is focused on the development of precision medicine therapeutics to slow the progression of Alzheimer’s disease.
Iterion Therapeutic is developing novel cancer therapeutics targeting nuclear β-catenin, a historically “undruggable” oncology target implicated in cell proliferation.
IMV is developing a novel suite of immunotherapeutics producing a more rapid, robust, and sustained immune response to target and treat specific diseases with unmet clinical needs.
G1 Therapeutics is focused on the development of small-molecule therapies to address high unmet needs in oncology including triple-negative breast cancer and extensive stage small cell lung cancer.
Fusion Pharmaceuticals is developing next-generation radio-pharmaceuticals as precision medicines for the treatment of cancer.
enGene is developing a platform that has the potential to streamline the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues.
Edesa Biotech is developing new treatments to help patients with limited options for inflammatory and immune-related diseases.
DEKA Biosciences is developing novel cytokine therapies to drive treatments for cancer patients and control inflammatory diseases.
DAMONA Pharmaceuticals is on a mission to develop small molecule therapeutics to improve the lives of patients suffering from cognitive impairment as a result of depression and other diseases of aging.
Cyrano Therapeutics is developing a novel therapy to restore chronic loss of taste and smell function in patients.
At the interface of computational and experimental drug discovery, Congruence Therapeutics is designing novel small molecules to treat diseases caused by protein misfolding.
Tackling the problem of resistance to current antifungal therapies, Bright Angel Therapeutics is developing novel therapeutics to treat these life-threatening invasive fungal infections.
BioTheryX is advancing a portfolio of first-in-class protein degraders to transform patient treatment across a wide range of inflammatory disorders and serious cancers.
Arclight Therapeutics is building a pipeline of early-stage companies focused on the development of novel therapeutics for neurodegenerative diseases.
AmacaThera is developing a unique, injectable hydrogel platform technology to deliver localized therapeutics that are long-lasting and applicable to several indications.
Antiva Biosciences is developing first-in-class topical therapies aimed at treating the pre-cancerous lesions caused by HPV infection.